CA3153685C - Systeme et methode pour l'elimination d'inhibiteurs immunitaires de fluides biologiques - Google Patents

Systeme et methode pour l'elimination d'inhibiteurs immunitaires de fluides biologiques Download PDF

Info

Publication number
CA3153685C
CA3153685C CA3153685A CA3153685A CA3153685C CA 3153685 C CA3153685 C CA 3153685C CA 3153685 A CA3153685 A CA 3153685A CA 3153685 A CA3153685 A CA 3153685A CA 3153685 C CA3153685 C CA 3153685C
Authority
CA
Canada
Prior art keywords
stnf
capture
target component
tnf
body fluid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3153685A
Other languages
English (en)
Other versions
CA3153685A1 (fr
Inventor
Steven Josephs
Matthew Ong
Amir Jafri
Robert Segal
Stephen Prince
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunicom Inc
Original Assignee
Immunicom Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunicom Inc filed Critical Immunicom Inc
Priority to CA3165330A priority Critical patent/CA3165330A1/fr
Publication of CA3153685A1 publication Critical patent/CA3153685A1/fr
Application granted granted Critical
Publication of CA3153685C publication Critical patent/CA3153685C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/362—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3687—Chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood
    • A61M2202/0415—Plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/75—General characteristics of the apparatus with filters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • External Artificial Organs (AREA)

Abstract

Le présent système et la présente méthode sont utiles pour l'élimination des inhibiteurs immunitaires tels que les récepteurs solubles du facteur de nécrose tumorale du liquide corporel des patients atteints de cancer. Dans certains modes de réalisation, les récepteurs solubles du facteur de nécrose tumorale 1 et 2 sont éliminés sélectivement du plasma avec une efficacité de 80 % ou plus. Dans certains modes de réalisation, le système comprend un ligand de capture immobilisé d'un facteur de nécrose tumorale alpha à chaîne unique. Le système et la méthode sont utiles pour le traitement de différents types, stades et degrés de gravité de cancer.
CA3153685A 2019-11-19 2019-11-19 Systeme et methode pour l'elimination d'inhibiteurs immunitaires de fluides biologiques Active CA3153685C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3165330A CA3165330A1 (fr) 2019-11-19 2019-11-19 Systeme et methode pour l'elimination d'inhibiteurs immunitaires de fluides biologiques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/062177 WO2021101519A1 (fr) 2019-11-19 2019-11-19 Système et méthode pour l'élimination d'inhibiteurs immunitaires de fluides biologiques

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3165330A Division CA3165330A1 (fr) 2019-11-19 2019-11-19 Systeme et methode pour l'elimination d'inhibiteurs immunitaires de fluides biologiques

Publications (2)

Publication Number Publication Date
CA3153685A1 CA3153685A1 (fr) 2021-05-27
CA3153685C true CA3153685C (fr) 2022-10-11

Family

ID=75980821

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3165330A Pending CA3165330A1 (fr) 2019-11-19 2019-11-19 Systeme et methode pour l'elimination d'inhibiteurs immunitaires de fluides biologiques
CA3153685A Active CA3153685C (fr) 2019-11-19 2019-11-19 Systeme et methode pour l'elimination d'inhibiteurs immunitaires de fluides biologiques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA3165330A Pending CA3165330A1 (fr) 2019-11-19 2019-11-19 Systeme et methode pour l'elimination d'inhibiteurs immunitaires de fluides biologiques

Country Status (8)

Country Link
EP (1) EP3846875A4 (fr)
JP (2) JP7159493B2 (fr)
KR (2) KR102491518B1 (fr)
CN (1) CN114650852B (fr)
AU (3) AU2019474912B2 (fr)
CA (2) CA3165330A1 (fr)
IL (2) IL289438B2 (fr)
WO (1) WO2021101519A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3194403A1 (fr) * 2020-10-01 2022-04-07 Steven Josephs Lixiviation reduite d'un ligand
US11224858B1 (en) 2020-10-01 2022-01-18 Immunicom, Inc. Reduced leaching of a ligand
JP7632141B2 (ja) * 2021-07-14 2025-02-19 東レ株式会社 モジュール

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3901216B2 (ja) 1995-02-16 2007-04-04 株式会社カネカ 腫瘍壊死因子−αの吸着剤、吸着除去方法および前記吸着剤を用いた吸着器
US8197430B1 (en) * 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
JP4150838B2 (ja) 1999-11-02 2008-09-17 株式会社カネカ 充填物流出防止用フィルタ及びそれを装着した吸着器
EP1624785B1 (fr) * 2003-01-17 2013-07-17 Aethlon Medical, Inc. Procede de suppression de virus dans le sang par hemodialyse a affinite pour les lectines
JP2006288571A (ja) * 2005-04-08 2006-10-26 Toray Ind Inc 癌治療用吸着材および体外循環カラム
JP4925159B2 (ja) * 2005-10-12 2012-04-25 日機装株式会社 血液浄化装置
BRPI0816165A2 (pt) * 2007-08-31 2015-02-24 Univ Michigan Dispositivo de citaferese seletiva e seus métodos relacionados
JP2009178523A (ja) * 2008-02-01 2009-08-13 Kaneka Corp 可溶性腫瘍壊死因子受容体の吸着材、吸着方法および吸着装置
JP5341559B2 (ja) * 2009-03-03 2013-11-13 和雄 寺本 多孔性吸着材
US9717841B2 (en) 2012-09-11 2017-08-01 Gary L. McNeil Closed-circuit device and methods for isolation, modification, and re-administration of specific constituents from a biological fluid source
US9227005B2 (en) * 2013-03-14 2016-01-05 Brian J LeBerthon Method and device for treating cancer
WO2015130956A2 (fr) 2014-02-28 2015-09-03 Exosome Sciences, Inc. Diagnostics fondés sur des exosomes spécifiques du cerveau, et traitements extracorporels
US10639405B2 (en) 2014-07-22 2020-05-05 Asahi Kasei Medical Co., Ltd. Adsorbent for removing histone and purification device for liquid derived from living organism
EP3274010B1 (fr) * 2015-03-27 2019-10-02 Eliaz Therapeutics, Inc. Aphérèse sélective sur un patient
WO2018020285A2 (fr) * 2016-07-28 2018-02-01 Captec Medical Kft. Dispositif de capture d'écoulement et procédé d'élimination de cellules du sang
US20190247560A1 (en) * 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
DE102018104177A1 (de) 2018-02-23 2019-08-29 B. Braun Avitum Ag Vorrichtung zur Entfernung von Noxen aus Blut, extrakorporales Perfusionssystem mit einer solchen Vorrichtung sowie Verfahren zur Herstellung einer solchen Vorrichtung
EP3746151B1 (fr) * 2018-02-28 2024-04-24 Plas-Free Ltd. Dispositif extracorporel et matrice pour éliminer des protéines fibrinolytiques de liquides biologiques, méthodes et utilisations de ceux-ci

Also Published As

Publication number Publication date
IL289438B2 (en) 2023-09-01
EP3846875A1 (fr) 2021-07-14
WO2021101519A1 (fr) 2021-05-27
JP2023015053A (ja) 2023-01-31
KR102491518B1 (ko) 2023-01-20
IL289438A (en) 2022-02-01
CN114650852B (zh) 2024-08-06
JP7159493B2 (ja) 2022-10-24
AU2022203249A1 (en) 2022-06-23
CA3153685A1 (fr) 2021-05-27
KR20220039724A (ko) 2022-03-29
AU2022203249B2 (en) 2023-08-31
AU2019474912B2 (en) 2022-02-17
JP7514281B2 (ja) 2024-07-10
AU2019474912A1 (en) 2022-01-06
KR20230016032A (ko) 2023-01-31
EP3846875A4 (fr) 2021-07-14
IL289438B1 (en) 2023-05-01
JP2022535604A (ja) 2022-08-09
CA3165330A1 (fr) 2021-05-27
CN114650852A (zh) 2022-06-21
AU2023274130A1 (en) 2023-12-21
IL301912A (en) 2023-06-01

Similar Documents

Publication Publication Date Title
AU2022203249B2 (en) System and method for removal of immune inhibitors from biological fluids
US20220288294A1 (en) System and method for removal of immune inhibitors from biological fluids
EP2717941B1 (fr) Traitement du cancer
KR101703785B1 (ko) 염증 증상의 치료 방법
US20180038860A1 (en) Treating cancer
US20120323158A1 (en) Extracorporeal immunoadsorption treatment
AU2013224740A1 (en) Closed-circuit device and methods for isolation, modification, and re-administration of specific constituents from a biological fluid source
TWI762833B (zh) 自生物流體中移除免疫抑制劑之系統及方法
WO2012172343A2 (fr) Traitement de l'angiocholite sclérosante primitive
US20220409795A1 (en) Modified tnf as a capture ligand
EP2718310A2 (fr) Traitement de troubles mentaux

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220307

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240930

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240930

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260108

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260630

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260713